Nurses are less satisfied with careers, more likely to leave profession amid COVID pressures: survey
About half of nurses polled by AMN Healthcare said they were likely to encourage others to take up the profession in 2023, down from 64% in 2021.
Uncategorized
Great Britain proposes allowing CE marks until 2030 to minimize Brexit disruption
The extended timeline to create a new regulatory system in England, Scotland and Wales is intended to prevent medical device shortages.
Great Britain proposes allowing CE marks until 2030 to minimize Brexit disruption Read More »
Amazon closes Halo health tracking unit as wave of tech layoffs continues
As it eliminates 27,000 jobs this year, the tech giant is exiting the wearables sector, and its Halo devices will stop working on Aug. 1.
Amazon closes Halo health tracking unit as wave of tech layoffs continues Read More »
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting
Lipella Pharmaceuticals Inc. today announced that it has delivered a late-breaking presentation at the annual meeting of the American Urological Association (AUA) Annual Meeting in Chicago on April 30, 2023.
Turn Biotechnologies Shows Promise of Epigenetic Reprogramming to Rejuvenate Skin at SEASON Aesthetic Conference
Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
Crown Therapeutics’ PanOxyl® Prioritizes Skin Health and Hydration with Acne Care Product Reformulation and New Launch
Crown Therapeutics, a division of Crown Laboratories, is proud to announce that PanOxyl® is expanding its award-winning portfolio with its new PM Balancing Repair Moisturizer and reformulating the existing AM Oil Control Moisturizer.
CG Oncology Announces New Phase 2 Data with Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA® (pembrolizumab) in BCG-Unresponsive NMIBC
CG Oncology, Inc. announced updated data from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).
Kiromic BioPharma Announces FDA Authorization of IND to Initiate Phase 1 Clinical Trial Evaluating Deltacel in Non-Small Cell Lung Cancer
Kiromic BioPharma, Inc. today announces that the U.S. Food and Drug Administration (FDA) has authorized the Company’s Investigational New Drug (IND) application to initiate a Phase 1 clinical trial to evaluate Deltacel (KB-GDT-01) for patients with non-small cell lung cancer (NSCLC).
Charles River Laboratories Launches Next Generation Sequencing Services for Bacterial Identification and Fungal ID
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of Accugenix® Next Generation Sequencing for Bacterial Identification and Fungal Identification (Accugenix® NGS).
Pulse Biosciences Announces $65 Million Private Placement
Pulse Biosciences, Inc. today announced that it has entered into a stock purchase agreement with Robert W. Duggan, an experienced life sciences executive and the Company’s Executive Chairman, for the purchase of 10,022,937 shares of the Company’s common stock.
Pulse Biosciences Announces $65 Million Private Placement Read More »